The US Food and Drug Administration (FDA) has expanded the indication for the Sapien 3 transcatheter heart valve (Edwards Lifesciences) to include valve-in-valve replacement for high-risk patients ...
Edwards today presented new data at New York Valves 2026 supporting its transcatheter aortic valve replacement (TAVR) ...
A 3D fully endoscopic simultaneous aortic and mitral valve replacement surgery, capable of treating both mitral and aortic valve dysfunction with only a minimal incision between the ribs, has been ...
Among asymptomatic patients with aortic or mitral regurgitation, cardiac function remains stable over 3 years in those with moderate disease but worsens in those with severe disease, according to a ...
Recent developments of interest in cardiovascular medicine ...
THE ideal response to mitral commissurotomy includes a normal blood flow into the left ventricle without the need for an elevated pressure in the left atrium and the return of cardiac output to normal ...
Please provide your email address to receive an email when new articles are posted on . Edwards Lifesciences Corp. announced the FDA approved its transcatheter heart valve for use in aortic and mitral ...
THE case reported below illustrates two interesting and unusual phenomena. The first is the production of the physical signs and phonocardiographic evidence of aortic stenosis in a patient with mitral ...
Degenerative valvular heart disease, the most common form of valve disease in the Western world, can lead to aortic stenosis (AS) or mitral regurgitation (MR). In current guidelines for the management ...
Please provide your email address to receive an email when new articles are posted on . Abbott announced the FDA has approved its next-generation stented bioprosthetic surgical valves for the ...
The mechanisms leading to valve calcification were traditionally believed to be due to passive accumulation of hydroxyapatite mineral, but recent studies have shown active processes similar to those ...
WASHINGTON, DC — The US Food and Drug Administration has expanded the Sapien 3 THV (Edwards Lifesciences) approval indication to include transcatheter "replacement" of failed bioprosthetic valves in ...